Opportunity Information: Apply for PAR 10 281
Apply for PAR 10 281
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NEI Translational Research Program on Therapy for Visual Disorders (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.867 Vision Research.
- This funding opportunity was created on Sep 15, 2010 and posted on Sep 15, 2010.
- Applicants must submit their applications by Jan 25, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NEI Translational Research Program on Therapy for Visual Disorders (R24) is a National Eye Institute funding opportunity designed to push promising eye and vision research out of the lab and into the early stages of clinical development. It is aimed at projects that are specifically focused on creating new therapies for visual diseases and disorders, especially where success depends on bringing together multiple areas of expertise. NEI is signaling that many of the biggest bottlenecks in therapy development are not simply basic science questions, but practical, scientific, and technical hurdles that require coordinated work across disciplines, such as developing and optimizing gene therapies, cell-based therapies, and pharmacologic interventions.
A central idea of the program is team science. Rather than supporting a single investigator or a narrow set of experiments, this R24 program is meant to provide resources that enable integrated collaborations between scientists and clinicians who can collectively solve problems that are beyond the capacity of any one lab. The expectation is that applicants will assemble a multidisciplinary team with complementary skills (for example, molecular biology, vector design, pharmacology, biomaterials, animal modeling, imaging, clinical ophthalmology, biostatistics, regulatory and manufacturing know-how) and use that structure to answer key translational questions that stand between a concept and a viable treatment candidate.
The program is explicitly milestone-driven and endpoint-focused. Each supported project is expected to have a clearly defined, concrete endpoint that can be achieved within a five-year period: developing a specific treatment for a specific eye disease. The FOA emphasizes that the path to that endpoint should be laid out as a logical sequence of steps, broken into clear milestones. Those milestones should map directly onto therapy development activities that prepare the intervention for clinical testing, with the overall aim of producing a therapeutic approach that is ready to be evaluated in a clinical trial. In practical terms, that implies applicants should propose a structured development plan rather than an open-ended research agenda, and they should define measurable progress points that show whether the project is on track.
The funding mechanism is the NIH R24 Research Resources Grant. In this context, that mechanism supports the kind of collaborative, resource-intensive work often required for translational therapy development, such as establishing shared platforms, specialized models, standardized assays, optimization pipelines, and other coordinated capabilities that a single group typically cannot build alone. The FOA notes that award size and project duration can vary depending on the scope of the proposed work, and that the total number of awards and the amounts funded depend on the volume, quality, length, and budgets of the applications received. The opportunity lists an estimated total funding level of $1,500,000 for the program.
Eligibility is broad across the research and higher education landscape. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits that meet NIH eligibility requirements). The announcement also calls out eligibility for several institution types that NIH often highlights for inclusion, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions. There is no cost sharing or matching requirement.
Administratively, this is an NIH discretionary grant in the health category, associated with CFDA 93.867 (Vision Research). The Funding Opportunity Number is PAR-10-281. It was posted on September 15, 2010, with an original and current closing date listed as January 25, 2013, and an archive date of February 25, 2013. The sponsoring agency is the National Institutes of Health, through the National Eye Institute, and the full announcement was hosted on the NIH grants guide. Contact information in the listing points applicants to the NIH Office of Extramural Research (OER) webmaster for technical issues accessing the announcement.
Overall, the opportunity is best understood as support for coordinated translational development efforts in vision science: projects that define a single disease target and a single therapeutic strategy, organize an interdisciplinary team around the key development risks, and use a milestone-based plan to move the therapy to a point where clinical trial testing is realistically achievable within five years.
FAQs: NEI Translational Research Program on Therapy for Visual Disorders (R24)
What is this funding opportunity?
This is a National Eye Institute (NEI) funding opportunity that supports translational research aimed at moving promising eye and vision therapies out of the lab and into early stages of clinical development. It uses the NIH R24 Research Resources Grant mechanism and is focused on therapy development for visual diseases and disorders.
What is the main goal of the program?
The main goal is to advance a specific therapy for a specific eye disease or disorder toward clinical testing readiness. The program is intended to address practical scientific and technical hurdles that commonly block progress between discovery research and a viable treatment candidate.
What kinds of research projects does NEI want to support under this R24 program?
The program is designed for coordinated translational development efforts that target a single disease and a single therapeutic strategy, and that use a structured, milestone-based plan to reach a concrete development endpoint within five years.
Is this opportunity focused on basic science or translational development?
It is focused on translational development. NEI highlights that many bottlenecks are not only basic science questions but also practical, scientific, and technical hurdles that require coordinated, cross-disciplinary work to solve.
What therapeutic approaches are specifically mentioned as relevant?
The opportunity explicitly mentions gene therapies, cell-based therapies, and pharmacologic interventions as examples of therapeutic modalities that may require coordinated development and optimization.
What does NEI mean by "team science" in this program?
"Team science" refers to building an integrated, multidisciplinary collaboration rather than relying on a single investigator or a narrow experimental plan. The expectation is that applicants will assemble a team with complementary expertise so the group can tackle translational problems that are beyond what any one lab can handle alone.
What kinds of expertise are expected on the project team?
The announcement provides examples of relevant expertise, including molecular biology, vector design, pharmacology, biomaterials, animal modeling, imaging, clinical ophthalmology, biostatistics, and regulatory and manufacturing know-how. The program expects a multidisciplinary team with complementary skills aligned to the translational hurdles of the proposed therapy.
What does "milestone-driven" and "endpoint-focused" mean for applicants?
Applicants are expected to propose a development path laid out as a logical sequence of steps, broken into clear milestones. These milestones should be measurable progress points that map directly to therapy development activities and show whether the project is on track to reach its endpoint.
What endpoint is the program expecting projects to achieve?
The program expects each supported project to have a clearly defined, concrete endpoint that can be achieved within five years: developing a specific treatment for a specific eye disease. The overall aim is to produce a therapeutic approach that is ready to be evaluated in a clinical trial.
How long are projects expected to take under this program?
The program frames the expected endpoint as achievable within a five-year period, and applicants are expected to build a plan and milestones consistent with reaching a clinical-testing-ready stage within that timeframe.
What does the R24 mechanism support in this context?
In this program, the NIH R24 Research Resources Grant mechanism supports collaborative, resource-intensive work that enables translational therapy development. Examples described include establishing shared platforms, specialized models, standardized assays, optimization pipelines, and other coordinated capabilities that a single group typically cannot build alone.
Is the award size and project duration fixed?
No. The announcement notes that award size and project duration can vary depending on the scope of the proposed work. It also states that the number of awards and the amounts funded depend on the volume, quality, length, and budgets of applications received.
What is the estimated total funding level mentioned for this program?
The opportunity lists an estimated total funding level of $1,500,000 for the program.
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations. The listing includes both 501(c)(3) nonprofits and certain non-501(c)(3) nonprofits that meet NIH eligibility requirements.
Are minority-serving institutions specifically included in the eligible applicant types?
Yes. The announcement explicitly calls out eligibility for institution types NIH often highlights for inclusion, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions.
Is cost sharing or matching required?
No. The listing states there is no cost sharing or matching requirement.
What is the sponsoring agency and institute?
The sponsoring agency is the National Institutes of Health (NIH), through the National Eye Institute (NEI).
What is the Funding Opportunity Number?
The Funding Opportunity Number is PAR-10-281.
What is the CFDA number and program area?
The opportunity is associated with CFDA 93.867, which is Vision Research.
What type of grant is this categorized as?
It is described as an NIH discretionary grant in the health category, using the NIH R24 mechanism.
When was the opportunity posted and when did it close?
The listing states it was posted on September 15, 2010. It shows an original and current closing date of January 25, 2013, and an archive date of February 25, 2013.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants guide.
Who should be contacted for technical issues accessing the announcement?
The listing points applicants to the NIH Office of Extramural Research (OER) webmaster for technical issues related to accessing the announcement.
How should applicants think about structuring a competitive project concept for this program?
Based on the description, the program is best understood as support for coordinated translational development efforts that: (1) define a single disease target and a single therapeutic strategy, (2) organize an interdisciplinary team around the key development risks and hurdles, and (3) use a milestone-based plan aimed at reaching a point where clinical trial testing is realistically achievable within five years.
Browse more opportunities from the same category: Health
Next opportunity: Operations and Maintenance
Previous opportunity: Ecology of Infectious Diseases
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 281
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 281) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 10 282 Funding Number: PAR 10 282 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Ryan White Part B Supplemental Apply for HRSA 11 099 Funding Number: HRSA 11 099 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Institute on Aging Revision Requests for Active Program Projects (P01) Apply for PAR 10 284 Funding Number: PAR 10 284 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alliance for Information on Maternal and Child Health (AIM) Cooperative Agreement Program Apply for HRSA 11 111 Funding Number: HRSA 11 111 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Universal Newborn Hearing Screening and Intervention Apply for HRSA 11 039 Funding Number: HRSA 11 039 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| NHLBI Program Project Applications (P01) Apply for PAR 10 285 Funding Number: PAR 10 285 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthen and Improve the Nation s Capacity through National, Non profit, Professional Public Health Organizations to Increase Health Protection and Health Equity Apply for CDC RFA HM08 8050302SUPP10 Funding Number: CDC RFA HM08 8050302SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $980,000 |
| SUID/SIDS Prevention and Bereavement Support Resource Centers Apply for HRSA 11 104 Funding Number: HRSA 11 104 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Diagnosis and Management of Severe Febrile Illness Apply for USAID TANZANIA 10 011 RFA Funding Number: USAID TANZANIA 10 011 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $24,000,000 |
| International AIDS Education and Training Center Apply for HRSA 11 063 Funding Number: HRSA 11 063 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Clinical and Data Coordinating Center(s) for Parkinsons Disease Biomarkers Identification Network (PD BIN) (U01) Apply for RFA NS 11 005 Funding Number: RFA NS 11 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Mentoring Networks to Enhance the Clinician Investigator Workforce in Deafness and Other Communication Disorders (U24) Apply for RFA DC 11 001 Funding Number: RFA DC 11 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NHLBI Translational Research Implementation Program (TRIP) Limited Competition (P50) Apply for RFA HL 12 003 Funding Number: RFA HL 12 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,515,000 |
| NIMH Research Education Programs for HIV/AIDS Research (R25) Apply for PAR 11 002 Funding Number: PAR 11 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Domestic Violence Prevention Enhancement Leadership Through Allianc (DELTA) III Apply for CE09 90103CONT11 Funding Number: CE09 90103CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Affordable Care Act (ACA) Grants for School Based Health Centers Capital (SBHCC) Program Apply for HRSA 11 127 Funding Number: HRSA 11 127 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Epidemiolgic and Ecologic Determinants of Monkeypox in a Disease endemic Setting Apply for RFA CK 11 003 Funding Number: RFA CK 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NIH Directors Early Independence Awards (DP5) Apply for RFA RM 10 019 Funding Number: RFA RM 10 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01) Apply for PAR 11 003 Funding Number: PAR 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R21) Apply for PAR 11 004 Funding Number: PAR 11 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 281", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.